Name (Synonyms) | Correlation | |
---|---|---|
drug169 | Berzosertib Wiki | 1.00 |
drug288 | Carboplatin Wiki | 1.00 |
drug435 | Docetaxel Wiki | 1.00 |
drug733 | Laboratory Biomarker Analysis Wiki | 1.00 |
drug361 | Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D011471 | Prostatic Neoplasms NIH | 1.00 |
D002277 | Carcinoma NIH | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012125 | Prostate cancer HPO | 1.00 |
HP:0030731 | Carcinoma HPO | 0.71 |
There is one clinical trial.
This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in two groups, RT PCR-positive and asymptomatic or mildly symptomatic at baseline (group B) and PCR-negative at baseline (group C). Both groups will be randomized 1:1 to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%).
Description: The efficacy of treatment will be determined by rating disease severity on Day 28, or last rating evaluated, using a seven-category severity scale.
Measure: Rate of Severe Disease Time: Up to 28 daysDescription: To compare the rate of measurable anti-SARS-CoV-2 titers between recipients of CP (anti-SARS-CoV-2 plasma) versus control (albumin 5%).
Measure: Rate of measurable anti-SARS-CoV-2 titers Time: Up to 90 daysDescription: Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).
Measure: Rate of SARS-CoV-2 PCR Positivity Time: Up to 28 daysDescription: Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).
Measure: Duration of SARS-CoV-2 PCR Positivity Time: Up to 28 daysDescription: Compare the levels of SARS-CoV-2 RNA between the recipients of antiSARS-CoV-2 plasma and control (albumin 5%)
Measure: Levels of SARS-CoV-2 RNA Time: Up to 28 days